S12 Ep15: Inavolisib Has a Favorable Risk-Benefit Profile for PIK3CA-Mutant, HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP

OncLive® On Air - A podcast by OncLive® On Air

Podcast artwork

Dr Jhaveri discusses advice for managing inavolisib-related adverse effects and best practices for biomarker testing in patients with HR+ breast cancer.